Warburg Pincus eyes Elan unit; Boehringer inks Chinese ingredients deal;

> Private equity firm Warburg Pincus is set to enter the race to aquire Elan's drug delivery unit, according to the Sunday Times. Report

> Boehringer Ingelheim has set up a production deal with China's Hisoar, under which Boehringer will provide technical expertise and Hisoar will build new facilties to produce raw materials for drugs. Report

> Meda and Cobalt Pharmaceuticals have settled their patent dispute over Astelin, a nasal spray, with a licensing deal that allows Cobalt to launch a generic version about three months before its U.S. patent expires in November 2010. Report

> India's Wockhardt got tentative FDA approval for its version of GlaxoSmithKline's Imitrex injection drug for migraines. Report

> Soaring prices of raw materials imported from China have pushed up the sticker price of branded drugs in Indonesia by 5 percent to 10 percent. Report

> Celera tapped former FDA Chief Counsel Peter Barton Hutt to serve on its board of directors. Report

> Back in May, Bothell, WA-based Sonus Pharmaceuticals announced plans to merge with OncoGenex Technologies and operate under the name OncoGenex Pharmaceuticals. Today the new company started things off by cutting almost half of its workforce. Report

> Biotech diagnostics company Proteome Systems announced today that it will no longer pursue efforts to develop the portfolio of therapeutic compounds the company acquired through its 2005 merger with Eukarion. Report

And Finally... Fifteen percent of seniors stopped taking their meds last year when they hit the so-called "doughnut hole" gap in Medicare Part D drug coverage. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.